Inactive

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulat... This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 “Streamlined Procedures for Evaluation and solicitation for commercial Items,” as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2056068 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-02, Effective 11/23/2020. The North American Industry Classification System (NAICS) code for this procurement is 334516, Analytical Laboratory Instrument, large business 1000 employees. This requirement is NOT set-aside for small business. This is a brand name acquisition. Background: The mission here at the Vaccine Research Center is to determine the immune correlates of protection against emerging infectious diseases. One of the specific aims of the lab is to understand processes that determine the course of human diseases in which the immune system plays a central role in their pathogenesis and outcome. We use the knowledge gained from studies on human disease directly in humans, with as little in vitro manipulation as possible to initiate clinical studies of new therapeutic and vaccine approaches. Many of our current projects will investigate RNA expression profiles of cell subsets from HTVN505 volunteers to identify markers are predictive of susceptibility to HIV acquisition. By far, the most robust approach to measure gene expression is RNA sequencing (RNAseq). Description and purpose of the Requirement: This request is for the MAGPIX analyzer that will be used to perform up to 50 assays. This new equipment is needed to replace our and outdated plate reader. This plate reader is a critical component of several assays used by our lab. The MAGPIX platform is needed because it has the needed sensitivity and signal-to-noise ratio; 2) It has the needed flexibility to read both 96- well format plates in 60 minutes; 3) it has the multiplexing of up to 10 analytes per well which is needed for current research time restriction. 4. ) We need a platform to perform 50 tests in a single reaction volume. This brand of software is compatible and approved with current software and network systems. ALL OFFERORS MUST ALSO COMPLETE AND SIGN THE ATTACHED CERTIFICATION (VENDOR CERTIFICATION) 52.204-26 and include quote Place of Performance: 40 Convent Drive, Bethesda, Md 20892 Delivery Date: 30 days ARO *Please include your DUNS number on quote *Include response to FAR 52.204-26 (mandatory) and 52.204-24 (if applicable) and return with quote Submission shall be received not later than 10:00 a.m. EST, January 12, 2021. The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the following; price, capability to meet the requirements, delivery and the best value to the government. The following FAR provisions apply to this acquisition: FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Nov 2020) FAR 52.212-1 Instructions to Offerors Commercial Items (Jun 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (Nov 2020) Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements – Representation (Jan 2017) The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (Oct 2018) FAR 52-212-5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (Nov 2020) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.203-19 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements (Jan 2017) FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-19 Incorporation by Reference of Representations and Certifications (Dec 2014) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (Dec 2015) By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Offers may be mailed, e-mailed or faxed to Lorena Waller (E-Mail/Wallerlor@niaid.nih.gov 240-669-5099). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) (June 2020) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Ms. Lorena Waller at Wallerlor@niaid.nih.gov.